Log In
BCIQ
Print this Print this
 

GDC-0310, RG6029

  Manage Alerts
Collapse Summary General Information
Company Genentech Inc.
Description Selective Nav1.7 (SCN9A) inhibitor
Molecular Target Nav1.7 (SCN9A)
Mechanism of ActionNav1.7 (SCN9A) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationPain
Indication DetailsTreat pain
Regulatory Designation
PartnerRoche;
Xenon Pharmaceuticals Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

01/16/2012

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today